Investigating how protein changes contribute to Ebola virus disease.
Research Project 3: Role of Posttranslational Protein Modifications in the Pathogenesis of Ebola Virus Disease
This study is looking at how changes to proteins in the body might affect the way the Ebola virus behaves and causes illness, with the hope that this could help find new treatments or vaccines for people affected by Ebola.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-11105949 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of posttranslational protein modifications in the development of Ebola virus disease. By examining how these modifications affect the virus's behavior and interaction with the host, the research aims to uncover potential mechanisms that lead to disease progression. The approach involves advanced molecular biology techniques to analyze protein changes in infected cells. Patients may benefit from insights gained that could lead to new therapeutic strategies or vaccines against Ebola virus disease.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit would include individuals at risk of Ebola virus exposure or those living in endemic regions.
Not a fit: Patients who are not at risk of Ebola virus exposure or who do not live in affected areas may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments or preventive measures for Ebola virus disease.
How similar studies have performed: While research on Ebola has been conducted, the specific focus on posttranslational modifications is a novel approach that has not been extensively tested.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Bukreyev, Alexander — University of Texas Med Br Galveston
- Study coordinator: Bukreyev, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.